Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Company Limited

The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood...

US FDA investigates death tied to Takeda's blood disorder drug

H.C. Wainwright has reaffirmed a Buy rating for Takeda Pharmaceutical Co Ltd, setting a price target of 80. The firm emphasized that a recent appro...

H.C. Wainwright reaffirms Buy for Takeda, targeting 80. Recent approval highlights strong at-home dosing label for all diagnosed cases.

Takeda Pharmaceutical Company Limited has reported promising interim data from its Phase 1b study of mezagitamab, an investigational anti-CD38 mono...

Takeda's mezagitamab shows stable kidney function and reduced proteinuria in IgA nephropathy patients. Phase 3 trials are advancing, indicating str...

Takeda Pharmaceutical Co Ltd has announced the completion of its pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) tri...

Takeda's dengue vaccine trial completion boosts confidence. The firm enhances its vaccine R&D alongside oncology and rare disease focus.

Takeda Pharmaceutical Co Ltd has completed its seven-year Phase 3 TIDES trial for its dengue vaccine, QDENGA. The trial data indicate that a two-do...

Takeda's QDENGA vaccine shows long-term efficacy against dengue, enhancing protection with booster doses. It's now authorized in 41 countries, bols...

Takeda Pharmaceutical Co Ltd reported its first half FY2025 results, showing a decline in key financial metrics. Revenue fell to 2.219 trillion yen...

Takeda's FY2025 results show declining revenue and profits. Adjusted EPS guidance cut reflects ongoing financial challenges.

Takeda Pharmaceutical Co. Ltd. announced today that its recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patient...

Takeda's HyHub devices simplify SCIg infusion for patients. This innovation enhances patient experience and could drive increased adoption of HYQVI...

Takeda Pharmaceutical Co Ltd has announced a significant global strategic partnership with Innovent Biologics, detailed in multiple releases within...

Takeda partners with Innovent for $1.2B cancer treatments. This strategic move aims to expand global access to innovative therapies.

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical , deepe...

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership

Takeda Pharmaceutical Co., Ltd. has announced a multi-year research collaboration with Nabla Bio, focusing on antibody design utilizing generative...

Takeda partners with Nabla Bio to boost antibody design. The collaboration aims to enhance early-stage development through advanced AI technology.

Takeda Pharmaceutical Co Ltd (TAK) has seen a decline of 2.6% today, coinciding with a notable drop in the iShares MSCI Japan ETF (EWJ), which has...

Takeda's stock declines amid falling EWJ, driven by inflation fears from the Bank of Japan's survey. Consumer sentiment impacts Takeda's market per...

Takeda Pharmaceutical Co Ltd is experiencing a price increase, aligned with a broader upward movement in the Pharmaceuticals sector. This positive...

Takeda's price rise reflects positive sentiment in Japan's pharmaceuticals sector. Growth in the services sector boosts investor confidence.

Takeda Pharmaceutical Co Ltd has seen a price drop of 2.3% since Wednesday. A social media post from yesterday after market hours suggested that Ta...

Takeda's price drop follows concerns over its superficial exit from cell therapy. The focus on established treatments signals strategic shifts amid...

Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a partner to advance candidat...